anna gidari - Infectious Diseases

Author Information

Anna Gidari is affiliated with the Department of Medicine at the Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, located in Perugia, Italy. Her research focuses primarily on infectious diseases, with a notable emphasis on the epidemiology and virology of SARS-CoV-2.

Research Contributions

Anna Gidari has made significant contributions to the understanding of SARS-CoV-2, the virus responsible for COVID-19. Her research spans various aspects of the virus, including its phylogeography, genomic epidemiology, and the interaction between the virus and host cellular mechanisms. She has explored the impact of SARS-CoV-2 on cellular glutathione metabolism, the efficacy of different detection methods for nucleocapsid protein antigen, and the predictive factors for COVID-19 prognosis. Her work also includes studies on the cross-neutralization of different SARS-CoV-2 variants and the effectiveness of early warning scores in predicting COVID-19 illness severity.

Aliases

There are no aliases provided for Anna Gidari in the available data.

Publication and Citation Metrics

Metric	Value
Total Citation Count	394
H-index	10
Total Paper Count	25

Publications:

Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020

DOI: 10.1038/s41598-022-09738-0

Year: 2022

Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected

DOI: 10.1016/j.jinf.2021.07.019

Year: 2021

Discovery of a AhR flavonoid agonist that counter-regulates ACE2 expression in rodent models of inflammation and attenuates ACE2-SARS-CoV2 interaction in vitro

DOI: 10.1101/2021.02.24.432203

Year: 2021

SARS-CoV2 infection impairs the metabolism and redox function of cellular glutathione

DOI: 10.1016/j.redox.2021.102041

Year: 2021

Role of Nucleocapsid Protein Antigen Detection for Safe End of Isolation of SARS-CoV-2 Infected Patients with Long Persistence of Viral RNA in Respiratory Samples

DOI: 10.3390/jcm10184037

Year: 2021

Predictive risk factors for worse outcomes in COVID-19 patients with different clinical features at baseline

DOI: 10.5114/AOMS/130374

Year: 2021

Low Brachial Artery Flow-Mediated Dilation Predicts Worse Prognosis in Hospitalized Patients with COVID-19

DOI: 10.3390/jcm10225456

Year: 2021

National Early Warning Score 2 (NEWS2) better predicts critical Coronavirus Disease 2019 (COVID-19) illness than COVID-GRAM, a multi-centre study

DOI: 10.1007/s15010-021-01620-x

Year: 2021

SARS-CoV-2 Survival on Surfaces and the Effect of UV-C Light

DOI: 10.3390/v13030408

Year: 2021

Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction

DOI: 10.1016/j.bcp.2021.114564

Year: 2021

What Tests are Performed on Stool Samples?

What is Ebola?

What is Immunodeficiency?

What Measures are Taken to Control Outbreaks?

What Causes Headaches in Infectious Diseases?

What Are the Components of the DTaP Vaccine?

What Role Do Public Health Organizations Play?

How do socio-economic factors influence the spread of infectious diseases?

What About Parasitic Pathogens?

What Are the Limitations of Blood Tests?

Partnered Content Networks

Relevant Topics